{
    "2021-10-21": [
        [
            {
                "time": "",
                "original_text": "北向资金持续加仓三日抢购A股超180亿，中国平安获大幅净买入超10亿",
                "features": {
                    "keywords": [
                        "北向资金",
                        "加仓",
                        "中国平安",
                        "净买入"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药（600276）：降本增效初见成效 国际化加速",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "降本增效",
                        "国际化"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "中泰证券维持恒瑞医药买入评级：业绩短期承压，静待丰厚创新成果兑现",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "买入评级",
                        "业绩承压",
                        "创新成果"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "孙飘扬复出难改恒瑞医药颓势，三季度公司营收净利润双降 盈利能力下降",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "孙飘扬",
                        "营收净利润双降",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "天风证券维持恒瑞医药买入评级：创新研发再升级，海外战略稳步推进",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "买入评级",
                        "创新研发",
                        "海外战略"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "三季报披露渐入高潮：医药公司业绩表现喜忧参半",
                "features": {
                    "keywords": [
                        "三季报",
                        "医药公司",
                        "业绩表现",
                        "喜忧参半"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "三季度营收净利润双降 恒瑞医药遭陆股通减持逾5000万股 盈利能力下降",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "营收净利润双降",
                        "陆股通减持",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "融资客青睐10股，方邦股份买入占比高达44.03%",
                "features": {
                    "keywords": [
                        "融资客",
                        "方邦股份",
                        "买入占比"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "A股融资融券日报：两融余额增加49.12亿元（10月20日）",
                "features": {
                    "keywords": [
                        "A股",
                        "融资融券",
                        "两融余额增加"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[国金晨报]上调福莱特、万华化学盈利预测；下调恒瑞医药盈利预测",
                "features": {
                    "keywords": [
                        "国金晨报",
                        "福莱特",
                        "万华化学",
                        "恒瑞医药",
                        "盈利预测"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "化工",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药（600276）：转型阵痛期 加速创新研发及国际化",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "转型阵痛期",
                        "创新研发",
                        "国际化"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药三季报：最坏的日子还未到",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "三季报",
                        "最坏的日子"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}